Tag: COVID-19
CureVac is an Underappreciated Opportunity, Says UBS
Investors may want to keep an eye on CureVac (CVAC).
After pulling back from about $12.50 to $10.50, CVAC could see higher highs. In fact,...
This is Why Pfizer Just Popped, As We Expected
Pfizer is pushing to higher highs.
In fact, as we noted on November 2, “After finding support around $41, the vaccine stock bolted to nearly...
Three of the Best Ways to Hedge for Volatility
Volatility could easily rocket higher with a great deal of uncertainty.
“We expect volatility to increase over the next month driven by a seasonal pickup...
Why Cruise Stocks Could Sink Even More
Cruise stocks are getting sunk.
All thanks to the spread of the coronavirus all around the world.
In the U.S. for example, according to CNBC, “Cases...
The 2021 Tokyo Olympics Could be Canceled
The Tokyo Olympics may not happen.
Just weeks ahead of the games, Japan is seeing a significant number of new COVID-19 cases, leading to calls...
Ocugen Could Easily Soar to Higher Highs
Ocugen has been explosive.
Since December 2020, the stock ran from a low of 29 cents to $13 good for a return of 4,383%. However,...
Johnson & Johnson (JNJ) May Be Ready to Rebound
Keep an eye on Johnson & Johnson (JNJ).
After pulling back from a high of $173.65, it caught support at $161.99. From here, the stock...
How to Trade the Wild Market Uncertainty
Uncertainty is driving markets nuts again.
All on talk of impeachment, and ahead of Joe Biden’s inauguration.
At the moment, House Democrats care calling on Vice...
The Top 3 Vaccine Trades that Should be in All Portfolios
Moderna (MRNA) has been incredibly explosive for us.
The first time we highlighted opportunity, the stock traded at $72 on Oct. 20. At the moment,...
This is Why Moderna Could Run to $200, Near-Term
Vaccine news has created big opportunity.
Look at BioNTech for example. The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had...
Popular Post
